Streetbeat News

Regulatory

COMS

COMSovereign Holding Corp. (NASDAQ:COMS) has regained its current filer status by filing its overdue quarterly reports for Q1, Q2, and Q3 of 2023. The company has reduced general and administrative expenses significantly through corporate streamlining, which has also improved its reporting processes. COMSovereign filed its 2022 annual report on December 7, 2023, after appraising goodwill and intangibles across its 16 operating units. The company has been restructuring, including selling off certain assets, to simplify its organization and reduce costs. The CEO, David Knight, emphasizes the company's focus on meeting Nasdaq and SEC requirements and supporting customer and partner needs, aiming for growth in 2024.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:23 pm

BBLG

Bone Biologics Corporation (BBLG) has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Capital Market. The company's stock had previously failed to meet the $1.00 minimum closing bid price for 30 consecutive days but has now maintained a price above $1.00 for 10 consecutive trading days as of January 4, 2024. Bone Biologics will be monitored by Nasdaq until June 28, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:22 pm

GSK

PFE

ViiV Healthcare, which is majority-owned by GSK and has Pfizer and Shionogi as stakeholders, has submitted a New Drug Submission for Cabotegravir to Health Canada for Pre-exposure Prophylaxis (PrEP). The submission is currently under priority review, which could expedite the approval process.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:16 pm

SECO

Secoo Holding Limited has received an additional delinquency letter from Nasdaq due to the late filing of its Form 6-K. The company is already non-compliant with Nasdaq's listing rules after failing to file its annual report on Form 20-F. Secoo has been given a deadline to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 days to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:07 pm

MRTX

The European Commission has granted approval to Mirati Therapeutics' Krazati (Adagrasib) for the treatment of KRASG12C-mutated advanced non-small cell lung cancer in patients who have undergone at least one prior systemic therapy. This marks a significant regulatory milestone for Mirati Therapeutics, potentially impacting its market presence in Europe.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:04 pm

KERN

Akerna Corp. (NASDAQ:KERN) has announced a special meeting for stockholders to vote on a proposed merger with Gryphon Digital Mining, Inc. The meeting is scheduled for January 29, 2024. The SEC has declared effective Akerna's Form S-4 registration statement related to the merger. The merger aims to create a carbon-neutral bitcoin miner, with the new entity to be listed on Nasdaq under the ticker 'GRYP'. The transaction is subject to stockholder approval and customary closing conditions, with a target close date of January 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:04 pm

AMGN

XERS

Xeris Biopharma has signed an exclusive worldwide license agreement with Amgen for the Xeriject formulation of teprotumumab, used for treating Thyroid Eye Disease. Xeris could receive up to $75M in development and regulatory milestones.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:03 pm

COIN

MARA

MSTR

RIOT

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:49 pm

COIN

ISRG

JNPR

KBH

NVDA

QQQ

SPY

TSLA

US stocks are poised for a mixed open as traders await the SEC's decision on a spot Bitcoin ETF, which could influence crypto and related stocks. The market is also anticipating Thursday's inflation data. On Tuesday, stocks mostly closed lower, with the Dow, S&P 500, and Russell 2000 down, while the Nasdaq Composite ended slightly higher. Analyst Ryan Detrick remains bullish for 2024 but expects early 2023 weakness. In premarket trading, SPY and QQQ rose, while TSLA, NVDA, and ISRG saw gains, and COIN and JNPR experienced movements tied to specific news. KBH is set to report earnings after market close.

Portfolio Pulse from Shanthi Rexaline

January 10, 2024 | 12:36 pm

CMND

Clearmind Medicine has completed a Type A meeting with the FDA regarding the clinical trial of its proprietary MEAI-based compound, CMND-100, aimed at treating Alcohol Use Disorder.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:21 pm